To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.
X
Search

NCCIT (ATCC® CRL-2073™)

Organism: Homo sapiens, human  /  Tissue: anterior mediastinal mixed germ cell tumor  /  Disease: pluripotent embryonal carcinoma; teratocarcinoma

Organism Homo sapiens, human
Tissue anterior mediastinal mixed germ cell tumor
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease pluripotent embryonal carcinoma; teratocarcinoma
Age adult
Gender male
Ethnicity Japanese
Images
Derivation
NCCIT was established by Shinichi Teshima (National Cancer Institute, Tokyo, Japan) in 1985 from a mediastinal mixed germ cell tumor.
Clinical Data
adult
Japanese
male
Tumorigenic Yes
Effects
Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 107 cells.
Comments
This pluripotent stem cell line is capable of somatic and extraembryonic differentiation.
The undifferentiated cells are equivalent to a stage intermediate between seminoma and embryonal carcinoma.
They will differentiate in response to retinoic acid.
NCCIT cells are negative for keratin.
They are positive for vimentin and placental alkaline phosphatase.
The line was contaminated with mycoplasma, but was cured by the depositor prior to deposit at the ATCC.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin. Let the culture sit at room temperature (or at 37°C) for 2 to 5 minutes. Add fresh medium, aspirate and dispense into new flasks. Subculture two times weekly.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Add fresh medium at the time of subculture
Cryopreservation
Culture medium, 95%; DMSO, 5%
STR Profile
Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 9,12
D5S818: 10,13
D7S820: 10
TH01: 7,9
TPOX: 8
vWA: 14,18
Name of Depositor I Damjanov
Deposited As Homo sapiens
Year of Origin 1985
References

Damjanov I, et al. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab. Invest. 68: 220-232, 1993. PubMed: 7680083

Teshima S, et al. Four new human germ cell tumor cell lines. Lab. Invest. 59: 328-336, 1988. PubMed: 2842544

Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
Cell Micrograph
References

Damjanov I, et al. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab. Invest. 68: 220-232, 1993. PubMed: 7680083

Teshima S, et al. Four new human germ cell tumor cell lines. Lab. Invest. 59: 328-336, 1988. PubMed: 2842544